Interactions between LOXL4 and oxidative stress pathway (WP3670)

Homo sapiens

This pathway Involved in chemo-resistance of cells in bladder cancer begins with LOXL2 activation of CDC37 and COL2A1. COL2A1 activates the complex NRF1/2 and two other complexes that trigger RTK/MAPK and TGFB pathways. These pathways along with oxidative stress promotes NRF1/2 activation of theoxidative stress pathway. This pathway promotes the transcription of NQO1, ECSIT, EXOC6, and SIRT1. SIRT1 then activates SUV39H1. LOXL2 also activates some of these proteins downstream in the pathway (SUV39H1, EXOC6, ECSIT). This pathway has been modeled after figure 7 in Deng et al. Proteins on this pathway have targeted assays available via the [ CPTAC Assay Portal].


AAR&Co , Alex Pico , Kristina Hanspers , Friederike Ehrhart , and Eric Weitz


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens



Pathway Ontology

oxidative stress response pathway urinary bladder cancer pathway disease pathway regulatory pathway

Disease Ontology

urinary bladder cancer


Label Type Compact URI Comment
SIRT1 GeneProduct ensembl:ENSG00000096717
ECSIT GeneProduct ensembl:ENSG00000130159
LOXL4 GeneProduct ensembl:ENSG00000138131
NQO1 GeneProduct ensembl:ENSG00000181019
NRF1 GeneProduct ensembl:ENSG00000106459
TGFB1 GeneProduct ensembl:ENSG00000105329
NFE2L2 GeneProduct ensembl:ENSG00000116044
CDC37 GeneProduct ensembl:ENSG00000105401
BMP2 GeneProduct ensembl:ENSG00000125845
COL2A1 GeneProduct ensembl:ENSG00000139219
SUV39H1 GeneProduct ensembl:ENSG00000101945
EXOC6 GeneProduct ensembl:ENSG00000138190
PKD1 GeneProduct ensembl:ENSG00000008710
FN1 GeneProduct ensembl:ENSG00000115414
ANXA5 GeneProduct ensembl:ENSG00000164111
FGF7 GeneProduct ensembl:ENSG00000140285
DDR1 GeneProduct ensembl:ENSG00000204580
IGFBP7 GeneProduct ensembl:ENSG00000163453


  1. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the oxidative stress pathway. Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, et al. Mol Cancer. 2014 Oct 14;13:234. PubMed Europe PMC Scholia